Powder: -20°C for 3 years | In solvent: -80°C for 1 year
VULM 1457 is a potent ACAT inhibitor. VULM 1457 has remarkable hypolipidaemic activity and improves the overall myocardial ischaemia-reperfusion injury outcomes. VULM1457 significantly reduces production and secretion of adrenomedullin (AM) and down-regulates AM receptors on human hepatoblastic cells.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 48.00 | |
2 mg | In stock | $ 68.00 | |
5 mg | In stock | $ 97.00 | |
10 mg | In stock | $ 163.00 | |
25 mg | In stock | $ 319.00 | |
50 mg | In stock | $ 578.00 | |
100 mg | In stock | $ 833.00 | |
500 mg | In stock | $ 1,690.00 |
Description | VULM 1457 is a potent ACAT inhibitor. VULM 1457 has remarkable hypolipidaemic activity and improves the overall myocardial ischaemia-reperfusion injury outcomes. VULM1457 significantly reduces production and secretion of adrenomedullin (AM) and down-regulates AM receptors on human hepatoblastic cells. |
In vitro | Preincubation of HepG2 cells with VULM1457 (0.1 μM) significantly reduced the specific [125I]AM binding on hypoxic cells with BmaxHypox being 127±10 and KD 0.06±0.11 nM. Preincubation of cells with VULM1457 (0.1 μM) significantly enhanced the number of cells (24.2±6 %) and higher concentrations of VULM1457 (1.0 and 10.0 μM) reduces the total number of cells[2]. In HepG2 cell lines, VULM1457 (0.03 μM; 0.1 μM) significantly down-regulated specific AM receptors on HepG2 cells, and reduced AM secretion of HepG2 cells exposed to hypoxia. VULM1457 negatively regulates cell proliferation induced by AM[2]. |
In vivo | In male Wistar rats, VULM 1457 protected the hearts of diabetic–hypercholesterolaemic rats against ischemia/reperfusion injury in vivo[1]. VULM 1457 (50 mg/kg/day) significantly decreases plasma total cholesterol levels (1.7±0.1 mM vs. 2.9±0.5 mM in diabetic–hypercholesterolaemic animals). The hypolipidaemic effect of VULM 1457 is also observed in the liver of DM-HCH rats (3.9±0.2 mg/g vs. 7.4±1.0 mg/g)[1]. |
Molecular Weight | 449.57 |
Formula | C25H27N3O3S |
CAS No. | 228544-65-8 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: < 44.96 mg/mL
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
VULM 1457 228544-65-8 Metabolism Acyltransferase acyl-CoA:cholesterol acyltransferase hypercholesterolaemia Diacylglycerol acyltransferase ischaemia-reperfusion myocardial Diglyceride acyltransferase mono- acylglycerol acyltransferase Inhibitor acyl-CoA VULM-1457 cholesterol acyltransferase VULM1457 hypolipidaemic inhibit diabetes mellitus inhibitor